Moderna Inc. (MRNA) Stock: Should Investors Follow These Insider Trades?


Moderna Inc. (NASDAQ:MRNA) saw a downside of -0.09% to close Tuesday at $196.76 after subtracting -$0.18 on the day. The 5-day average trading volume is 4,827,680 shares of the company’s common stock. It has gained $207.51 in the past week and touched a new high 1 time within the past 5 days. An average of 4,201,550 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 5,288,330.

MRNA’s 1-month performance is -6.32% or -$2.32 on its low of $171.40 reached on 01/06/23. The company’s shares have touched a 52-week low of $115.03 and high of $217.25, with the stock’s rally to the 52-week high happening on 01/18/23. YTD, MRNA has achieved 9.54% or $17.14 and has reached a new high 6 times. However, the current price is down -9.43% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Insider Transactions

MRNA stock investors last saw insider trading activity on Jan 19.Bancel Stephane (Chief Executive Officer) most recently sold 40,000 shares at $192.06 per share on Jan 19. This transaction cost the insider $7,682,289. Chief Executive Officer, Bancel Stephane, sold 40,000 shares at a price of $197.96 on Jan 18. Then, on Jan 18, Director AFEYAN NOUBAR sold 10,000 shares at a price of $200.20 per share. This transaction amounted to $2,002,000.

Valuation Metrics

MRNA stock has a beta of 1.70. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.47 while the price-to-book (PB) in the most recent quarter is 4.27, with the price to cash flow ratio at 11.96.

Moderna Inc.’s quick ratio for the period ended June 29 was 1.80, with the current ratio over the same period at 2.10. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.05, while the total debt to equity was 0.06.. In terms of profitability, the gross margin trailing 12 months is 79.20%. The firm’s gross profit as reported stood at $15.85 billion against revenue of $18.47 billion.

Earnings Surprise

For the quarterly period ending June 29 this year, Moderna Inc.’s cash and short-term investments amounted to $5.32 billion against total debt of $887.0 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -219.56% to $1.04 billion, while revenue of $2.2 billion was -110.64% off the previous quarter. Analysts expected MRNA to announce $4.55 per share in earnings in its latest quarter, but it posted $5.24, representing a 15.20% surprise. EBITDA for the quarter stood at more than $1.28 billion. MRNA stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 8.06 billion, with total debt at $887.0 million. Shareholders hold equity totaling $384.18 million.

Let’s look briefly at Moderna Inc. (MRNA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 60.20% to suggest the stock is trending Neutral, with historical volatility in this time period at 30.96%.

The stock’s 5-day moving average is $195.02, reflecting a +3.18% or $6.07 change from its current price. MRNA is currently trading -5.56% above its 20-day SMA, +44.75% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +20.56% and SMA200 by+27.25%.

Stochastic %K and %D was 67.83% and 63.93% and the average true range (ATR) pointed at 8.58. The RSI (14) points at 57.55%, while the 14-day stochastic is at 70.23% with the period’s ATR at 9.33. The stock’s 9-day MACD Oscillator is pointing at 3.40 and 7.52 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Moderna Inc. (NASDAQ: MRNA), Jefferies upgraded it to a Buy rating. They previously had a Hold rating on the stock.


Please enter your comment!
Please enter your name here